INMED PHARMACEUTICALS INC. Depreciation
INMED PHARMACEUTICALS INC. (INM) reported Depreciation of $50.20 thousand for the 12-month period ending 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. depreciation for the quarter ending 2025-06-30 was $12.21K, a 124.37% increase year-over-year.
- INMED PHARMACEUTICALS INC. depreciation for the quarter ending 2025-03-31 was $12.20K, a 14.18% decline year-over-year.
- INMED PHARMACEUTICALS INC. depreciation for the quarter ending 2024-12-31 was $12.21K, a 14.27% decline year-over-year.
- INMED PHARMACEUTICALS INC. depreciation for the quarter ending 2024-09-30 was $13.59K, a 1.83% decline year-over-year.
- INMED PHARMACEUTICALS INC. depreciation for fiscal 2023 was $39.61K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2025-06-30 | $12.21K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $24.41K derived: sum of 2 quarters · filed 2026-07-02 | $36.62K derived: sum of 3 quarters · filed 2026-07-02 | $50.20K S-4 · filed 2026-07-02 |
| 2025-03-31 | $12.20K 10-Q · filed 2025-05-12 | $24.41K derived: sum of 2 quarters · filed 2025-05-12 | $38.00K 10-Q · filed 2025-05-12 | $43.44K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-12-31 | $12.21K 10-Q · filed 2025-02-12 | $25.80K 10-Q · filed 2025-02-12 | $31.23K derived: sum of 3 quarters · filed 2026-07-02 | $45.45K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-09-30 | $13.59K 10-Q · filed 2024-11-14 | $19.03K derived: sum of 2 quarters · filed 2026-07-02 | $33.25K derived: sum of 3 quarters · filed 2026-07-02 | $47.49K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-06-30 | $5.44K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $19.66K derived: sum of 2 quarters · filed 2026-07-02 | $33.90K derived: sum of 3 quarters · filed 2026-07-02 | $47.74K S-4 · filed 2026-07-02 |
| 2024-03-31 | $14.22K 10-Q · filed 2025-05-12 | $28.46K derived: sum of 2 quarters · filed 2025-05-12 | $42.30K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $14.24K 10-Q · filed 2025-02-12 | $28.08K 10-Q · filed 2025-02-12 | ||
| 2023-09-30 | $13.84K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $39.61K 10-K · filed 2024-09-30 | |||
| 2022-12-31 | $8.06K 10-Q · filed 2024-02-13 | $16.11K 10-Q · filed 2024-02-13 | ||
| 2020-09-30 | $21.35K 10-Q · filed 2020-12-17 | |||
| 2019-09-30 | $7.18K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |